Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics
LEGN Price/Volume Stats
| Current price | $49.75 | 52-week high | $70.78 |
| Prev. close | $49.80 | 52-week low | $38.60 |
| Day low | $49.18 | Volume | 398,500 |
| Day high | $50.32 | Avg. volume | 1,030,040 |
| 50-day MA | $54.61 | Dividend yield | N/A |
| 200-day MA | $54.39 | Market Cap | 9.07B |
LEGN Stock Price Chart Interactive Chart >
Legend Biotech Corp. ADR (LEGN) Company Bio
Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.
Latest LEGN News From Around the Web
Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.
13 High Growth Healthcare Stocks to BuyIn this article, we will take a look at 13 high growth healthcare stocks to buy. To skip our analysis of the recent market activity, you can go directly to see the 5 Best High Growth Healthcare Stocks to Buy. For the purpose of this article, we have defined high growth stocks as stocks that […] |
Patient-Reported Outcomes from the CARTITUDE-4 Study Showed Clinically Meaningful Improvements in Health-Related Quality of Life and Reductions in Multiple Myeloma Symptoms Following Treatment with CARVYKTI® (ciltacabtagene autoleucel)SOMERSET, N.J., December 12, 2023--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced today patient-reported outcome (PRO) data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology (ASH) Annual Meeting (Abstract #1063). These data showed clinically meaningful improvement in health-related quality of |
CAR T-Cell Therapies Under FDA Watch on Reports of MalignanciesThe FDA has undertaken an investigation of T-cell malignancies in patients undergoing CAR T-cell therapy treatment. Therapies from NVS, BMY and GILD are under the spotlight. |
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood CellsThe U.S. Food and Drug Administration is investigating certain CAR T cancer therapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment. |
Legend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call TranscriptLegend Biotech Corporation (NASDAQ:LEGN) Q3 2023 Earnings Call Transcript November 20, 2023 Legend Biotech Corporation beats earnings expectations. Reported EPS is $-0.17, expectations were $-0.56. Operator: Good day, ladies and gentlemen. Thank you for standing by. Welcome to Legend Biotech Reports Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in […] |
LEGN Price Returns
| 1-mo | -12.84% |
| 3-mo | 17.20% |
| 6-mo | -22.29% |
| 1-year | -23.91% |
| 3-year | 35.15% |
| 5-year | N/A |
| YTD | -17.32% |
| 2023 | 20.53% |
| 2022 | 7.10% |
| 2021 | 65.52% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...